Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT1006 in advanced HER2-positive solid tumors
NCT05414136Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT1006 in solid tumor (5 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose limiting toxicity at 21 days and Maximum tolerance dose at 21 days. Started Feb 2022; status: completed.
02
Drugs
BAT1006
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05414136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414136.